Form D · Pharmaceuticals
Response Pharmaceuticals, Inc.
Falls Church, VA · CIK 0001913970
Offering snapshot reported Jun 28, 2024 · SEC filing
- Reported sold
- $3.9M Offering amount: $5M
- Investors reported
- 51 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 13, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 28, 2024 | Initial | $3,898,385 | No comparison | 51 | SEC filing |
| Dec 5, 2022 | Amendment | $7,988,250 | $4,763,250vs Mar 1, 2022 | 127 | SEC filing |
| Mar 1, 2022 | Initial | $3,225,000 | No comparison | 47 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $286K
- Form D file number
- 021-517279
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Collage Venture Partners, LLC | 316063 | |
| Stonehaven, LLC | 118913 |
Source: Form D, filed Jun 28, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Berendt | Director |
| Eric Keller | Director, Executive |
| Donald Olds | Director |
| Paul Sweetnam | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1104 West Broad Street #1064
Falls Church, VA, 22046
Falls Church, VA, 22046